TITLE

Metabolic

AUTHOR(S)
Pines, Noah
PUB. DATE
March 2013
SOURCE
Medical Marketing & Media;Mar2013, Vol. 48 Issue 3, p42
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the potential for a drug that address both diabetes and obesity. It mentions the Invokana from Johnson & Johnson, which results to lower A1c level and hypoglycemia rates and it offers weight loss benefit. It states that some drugs for weight loss have not reach its expected status because people are very cautious. It says that Vivus markets its Qsymia through educational approach that the drug would treat metabolic syndrome in people.
ACCESSION #
85908697

 

Related Articles

  • First Qnexa Phase III Trial Hits Endpoints.  // Bioworld Week;12/15/2008, Vol. 16 Issue 50, p4 

    The article reports on the result of the first of three Phase III trials of Vivus Inc.'s obesity drug Qnexa. It demonstrates an average weight loss of 9.2% at a full-dose and 8.5 % at the mid-dose in comparison to the 1.7% for the placebo group. Results also show that Qnexa may fare better than...

  • Lemons for Obesity. Lauer, Michael S. // Annals of Internal Medicine;7/17/2012, Vol. 157 Issue 2, p139 

    The author discusses antiobesity medication Qnexa manufactured by Vivus Inc. and obesity medications in general. He discusses the drugs including Ephedra, Fen-phen and phenylpropanolamine which are withdrawn from the market due to cardiovascular toxicity. Clinical cardiovascular effects of Qnexa...

  • Nathealth Solutions Announces U.S. Launch of New Cholesterol-Lowering, Cardiovascular Health Supplement.  // Biomedical Market Newsletter;7/26/2012, Vol. 21, p1 

    The article informs that the nutritional supplement, BergaMet MEGA has been launched in the U.S. by Nathealth Solutions. It further informs that the supplement is used for the treatment of several medical conditions including metabolic syndrome, diabetes and obesity. It mentions the features of...

  • Obesity Data Show Drugs May Offer More Than Weight Loss. Hollingsworth, Catherine // BioWorld Today;6/30/2010, Vol. 21 Issue 125, p1 

    The article presents the highlights of scientific sessions on obesity drugs held by the American Diabetes Association (ADA) in Orlando, Florida in June 2010. Pharmaceutical companies such as Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc. and Vivus Inc. have presented data which showed...

  • Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p661 

    The article discusses a study conducted by researchers from Center for Applied Medical Research of the University of Navarra in Spain which reveals the potential of cadiotrophin 1 to treat metabolic syndrome and obesity.

  • EndoBarrier® Rapidly Improves Diabetes Parameters. Vinall, Maria // MD Conference Express;Dec2011, p11 

    The article presents a study on the efficacy of the drug EndoBarrier in the treatment of type 2 diabetes and obesity. It mentions that EndoBarrier produces long-lasting weight loss in patients, as well as improvement in diabetes and has beneficial hormonal effects. It notes that EndoBarrier also...

  • Ayurvedic Concept of Obesity, Metabolic Syndrome, and Diabetes Mellitus. Sharma, Hari; Chandola, H.M. // Journal of Alternative & Complementary Medicine;Jun2011, Vol. 17 Issue 6, p549 

    Obesity, metabolic syndrome, and diabetes mellitus are increasing to epidemic proportions globally. There are 400 million clinically obese adults worldwide and there are more than 220 million people who have diabetes. The global impact of these disorders is immense in terms of human suffering...

  • Europe's CHMP Bounces Vivus' Weight Loss Drug. Shaffer, Catherine // BioWorld Today;10/22/2012, Vol. 23 Issue 205, p1 

    The article reports on the decision of the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) to recommend against approval of Vivus Inc.'s obesity medicine Qsiva (phentermine/topiramate). The decision is based on concerns about potential cardiovascular and central...

  • NIH Study: No Cardio Benefit for Type II Diabetics.  // BioWorld Today;10/22/2012, Vol. 23 Issue 205, p4 

    The article reports on the decision of the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) to recommend against approval of Vivus Inc.'s obesity medicine Qsiva (phentermine/topiramate). The decision is based on concerns about potential cardiovascular and central...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics